487 related articles for article (PubMed ID: 25851829)
1. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
Marti JL; Jain KS; Morris LG
Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
[TBL] [Abstract][Full Text] [Related]
2. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
[TBL] [Abstract][Full Text] [Related]
3. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
4. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
[TBL] [Abstract][Full Text] [Related]
5. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
Bhattacharyya N; Chien W
Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
7. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
Reiners C; Schneider R; Platonova T; Fridman M; Malzahn U; Mäder U; Vrachimis A; Bogdanova T; Krajewska J; Elisei R; Vaisman F; Mihailovic J; Costa G; Drozd V
Front Endocrinol (Lausanne); 2020; 11():381. PubMed ID: 32754115
[TBL] [Abstract][Full Text] [Related]
9. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
10. Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study.
Wu W; Li S; Xu K; Meng Z
Endokrynol Pol; 2023; 74(3):260-270. PubMed ID: 37335064
[TBL] [Abstract][Full Text] [Related]
11. Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
Pasqual E; Schonfeld S; Morton LM; Villoing D; Lee C; Berrington de Gonzalez A; Kitahara CM
J Clin Oncol; 2022 May; 40(13):1439-1449. PubMed ID: 35044839
[TBL] [Abstract][Full Text] [Related]
12. Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study.
Piscopo L; Volpe F; Nappi C; Zampella E; Manganelli M; Matrisciano F; Totaro P; Pace L; Maurea S; Cuocolo A; Klain M
Curr Oncol; 2022 Dec; 30(1):37-44. PubMed ID: 36661652
[TBL] [Abstract][Full Text] [Related]
13. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study.
Spanogle JP; Clarke CA; Aroner S; Swetter SM
J Am Acad Dermatol; 2010 May; 62(5):757-67. PubMed ID: 20223559
[TBL] [Abstract][Full Text] [Related]
14. Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult.
Zhao X; Chen M; Qi X; Zhu H; Yang G; Guo Y; Dong Q; Yang Q
Front Endocrinol (Lausanne); 2021; 12():805194. PubMed ID: 35154006
[TBL] [Abstract][Full Text] [Related]
15. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer.
Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG
J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433
[TBL] [Abstract][Full Text] [Related]
16. Risk of second malignancies among survivors of pediatric thyroid cancer.
Adly MH; Sobhy M; Rezk MA; Ishak M; Afifi MA; Shafie AE; Ali MA; Zekri W; Alfaar AS; Rashed WM
Int J Clin Oncol; 2018 Aug; 23(4):625-633. PubMed ID: 29492793
[TBL] [Abstract][Full Text] [Related]
17. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
[TBL] [Abstract][Full Text] [Related]
18. Trends in the risk and burden of second primary malignancy among survivors of smoking-related cancers in the United States.
Adjei Boakye E; Buchanan P; Hinyard L; Osazuwa-Peters N; Simpson MC; Schootman M; Piccirillo JF
Int J Cancer; 2019 Jul; 145(1):143-153. PubMed ID: 30613963
[TBL] [Abstract][Full Text] [Related]
19. Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.
Mei X; Yao X; Feng F; Cheng W; Wang H
BMC Cancer; 2021 May; 21(1):543. PubMed ID: 33980182
[TBL] [Abstract][Full Text] [Related]
20. Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?
Souza MC; Momesso DP; Vaisman F; Vieira Neto L; Martins RA; Corbo R; Vaisman M
Arch Endocrinol Metab; 2016 Feb; 60(1):9-15. PubMed ID: 26222230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
